Antimicrobial effects of the saliva substitute, Oralbalance®, against microorganisms from oral mucosa in the hematopoietic cell transplantation period

Yuko Sugiura, Yoshihiko Soga, Ichiro Tanimoto, Susumu Kokeguchi, Sachiko Nishide, Kotoe Kono, Kanayo Takahashi, Nobuharu Fujii, Fumihiko Ishimaru, Mitsune Tanimoto, Kokoro Yamabe, Soichiro Tsutani, Fusanori Nishimura, Shogo Takashiba

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Goals: The commercially available saliva substitute Oralbalance® has been reported to alleviate symptoms of post-radiotherapy xerostomia in head and neck cancer patients. Oralbalance® may also be effective for xerostomia in patients undergoing hematopoietic cell transplantation (HCT) with high-dose chemotherapy and total-body irradiation. However, HCT patients are severely compromised, and saliva substitute must therefore not promote infection. This study was performed to determine the effects of Oralbalance® on microbial species identified during HCT. Patients and methods: Microbial identification of oral mucosa was performed in 28 patients undergoing HCT. The antimicrobial effects of Oralbalance® against bacteria and fungi detected in the HCT period were examined in vitro. Briefly, bacteria and fungi were spread on agar plates, and 0.1g of Oralbalance® gel was applied (about φ1cm). After incubation at 37°C for 24h, the presence of a transparent zone of inhibition around Oralbalance® was observed. Main results: Not only bacterial species constituting normal flora of the oral mucosa but also those not usually constituting normal flora, e.g., coagulase-negative Staphylococcus, were detected. A transparent zone was observed around Oralbalance® in all bacterial species examined. No transparent zone was observed for Candida albicans, but growth was inhibited in the area where Oralbalance® was applied. Conclusions: Oralbalance® does not facilitate increases in microorganisms in the HCT period. Oral care with Oralbalance® does not promote infection in patients undergoing HCT.

Original languageEnglish
Pages (from-to)421-424
Number of pages4
JournalSupportive Care in Cancer
Volume16
Issue number4
DOIs
Publication statusPublished - Apr 2008

Fingerprint

Cell Transplantation
Mouth Mucosa
Saliva
Xerostomia
Fungi
Bacteria
Whole-Body Irradiation
Coagulase
Head and Neck Neoplasms
Infection
Candida albicans
Staphylococcus
Agar
Radiotherapy
Gels
Drug Therapy
Growth

Keywords

  • Antimicrobial activity
  • Hematopoietic cell transplantation
  • Saliva substitute
  • Xerostomia

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Antimicrobial effects of the saliva substitute, Oralbalance®, against microorganisms from oral mucosa in the hematopoietic cell transplantation period. / Sugiura, Yuko; Soga, Yoshihiko; Tanimoto, Ichiro; Kokeguchi, Susumu; Nishide, Sachiko; Kono, Kotoe; Takahashi, Kanayo; Fujii, Nobuharu; Ishimaru, Fumihiko; Tanimoto, Mitsune; Yamabe, Kokoro; Tsutani, Soichiro; Nishimura, Fusanori; Takashiba, Shogo.

In: Supportive Care in Cancer, Vol. 16, No. 4, 04.2008, p. 421-424.

Research output: Contribution to journalArticle

Sugiura, Yuko ; Soga, Yoshihiko ; Tanimoto, Ichiro ; Kokeguchi, Susumu ; Nishide, Sachiko ; Kono, Kotoe ; Takahashi, Kanayo ; Fujii, Nobuharu ; Ishimaru, Fumihiko ; Tanimoto, Mitsune ; Yamabe, Kokoro ; Tsutani, Soichiro ; Nishimura, Fusanori ; Takashiba, Shogo. / Antimicrobial effects of the saliva substitute, Oralbalance®, against microorganisms from oral mucosa in the hematopoietic cell transplantation period. In: Supportive Care in Cancer. 2008 ; Vol. 16, No. 4. pp. 421-424.
@article{3d22908ad4c3499792b351769a7824ad,
title = "Antimicrobial effects of the saliva substitute, Oralbalance{\circledR}, against microorganisms from oral mucosa in the hematopoietic cell transplantation period",
abstract = "Goals: The commercially available saliva substitute Oralbalance{\circledR} has been reported to alleviate symptoms of post-radiotherapy xerostomia in head and neck cancer patients. Oralbalance{\circledR} may also be effective for xerostomia in patients undergoing hematopoietic cell transplantation (HCT) with high-dose chemotherapy and total-body irradiation. However, HCT patients are severely compromised, and saliva substitute must therefore not promote infection. This study was performed to determine the effects of Oralbalance{\circledR} on microbial species identified during HCT. Patients and methods: Microbial identification of oral mucosa was performed in 28 patients undergoing HCT. The antimicrobial effects of Oralbalance{\circledR} against bacteria and fungi detected in the HCT period were examined in vitro. Briefly, bacteria and fungi were spread on agar plates, and 0.1g of Oralbalance{\circledR} gel was applied (about φ1cm). After incubation at 37°C for 24h, the presence of a transparent zone of inhibition around Oralbalance{\circledR} was observed. Main results: Not only bacterial species constituting normal flora of the oral mucosa but also those not usually constituting normal flora, e.g., coagulase-negative Staphylococcus, were detected. A transparent zone was observed around Oralbalance{\circledR} in all bacterial species examined. No transparent zone was observed for Candida albicans, but growth was inhibited in the area where Oralbalance{\circledR} was applied. Conclusions: Oralbalance{\circledR} does not facilitate increases in microorganisms in the HCT period. Oral care with Oralbalance{\circledR} does not promote infection in patients undergoing HCT.",
keywords = "Antimicrobial activity, Hematopoietic cell transplantation, Saliva substitute, Xerostomia",
author = "Yuko Sugiura and Yoshihiko Soga and Ichiro Tanimoto and Susumu Kokeguchi and Sachiko Nishide and Kotoe Kono and Kanayo Takahashi and Nobuharu Fujii and Fumihiko Ishimaru and Mitsune Tanimoto and Kokoro Yamabe and Soichiro Tsutani and Fusanori Nishimura and Shogo Takashiba",
year = "2008",
month = "4",
doi = "10.1007/s00520-007-0391-z",
language = "English",
volume = "16",
pages = "421--424",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Antimicrobial effects of the saliva substitute, Oralbalance®, against microorganisms from oral mucosa in the hematopoietic cell transplantation period

AU - Sugiura, Yuko

AU - Soga, Yoshihiko

AU - Tanimoto, Ichiro

AU - Kokeguchi, Susumu

AU - Nishide, Sachiko

AU - Kono, Kotoe

AU - Takahashi, Kanayo

AU - Fujii, Nobuharu

AU - Ishimaru, Fumihiko

AU - Tanimoto, Mitsune

AU - Yamabe, Kokoro

AU - Tsutani, Soichiro

AU - Nishimura, Fusanori

AU - Takashiba, Shogo

PY - 2008/4

Y1 - 2008/4

N2 - Goals: The commercially available saliva substitute Oralbalance® has been reported to alleviate symptoms of post-radiotherapy xerostomia in head and neck cancer patients. Oralbalance® may also be effective for xerostomia in patients undergoing hematopoietic cell transplantation (HCT) with high-dose chemotherapy and total-body irradiation. However, HCT patients are severely compromised, and saliva substitute must therefore not promote infection. This study was performed to determine the effects of Oralbalance® on microbial species identified during HCT. Patients and methods: Microbial identification of oral mucosa was performed in 28 patients undergoing HCT. The antimicrobial effects of Oralbalance® against bacteria and fungi detected in the HCT period were examined in vitro. Briefly, bacteria and fungi were spread on agar plates, and 0.1g of Oralbalance® gel was applied (about φ1cm). After incubation at 37°C for 24h, the presence of a transparent zone of inhibition around Oralbalance® was observed. Main results: Not only bacterial species constituting normal flora of the oral mucosa but also those not usually constituting normal flora, e.g., coagulase-negative Staphylococcus, were detected. A transparent zone was observed around Oralbalance® in all bacterial species examined. No transparent zone was observed for Candida albicans, but growth was inhibited in the area where Oralbalance® was applied. Conclusions: Oralbalance® does not facilitate increases in microorganisms in the HCT period. Oral care with Oralbalance® does not promote infection in patients undergoing HCT.

AB - Goals: The commercially available saliva substitute Oralbalance® has been reported to alleviate symptoms of post-radiotherapy xerostomia in head and neck cancer patients. Oralbalance® may also be effective for xerostomia in patients undergoing hematopoietic cell transplantation (HCT) with high-dose chemotherapy and total-body irradiation. However, HCT patients are severely compromised, and saliva substitute must therefore not promote infection. This study was performed to determine the effects of Oralbalance® on microbial species identified during HCT. Patients and methods: Microbial identification of oral mucosa was performed in 28 patients undergoing HCT. The antimicrobial effects of Oralbalance® against bacteria and fungi detected in the HCT period were examined in vitro. Briefly, bacteria and fungi were spread on agar plates, and 0.1g of Oralbalance® gel was applied (about φ1cm). After incubation at 37°C for 24h, the presence of a transparent zone of inhibition around Oralbalance® was observed. Main results: Not only bacterial species constituting normal flora of the oral mucosa but also those not usually constituting normal flora, e.g., coagulase-negative Staphylococcus, were detected. A transparent zone was observed around Oralbalance® in all bacterial species examined. No transparent zone was observed for Candida albicans, but growth was inhibited in the area where Oralbalance® was applied. Conclusions: Oralbalance® does not facilitate increases in microorganisms in the HCT period. Oral care with Oralbalance® does not promote infection in patients undergoing HCT.

KW - Antimicrobial activity

KW - Hematopoietic cell transplantation

KW - Saliva substitute

KW - Xerostomia

UR - http://www.scopus.com/inward/record.url?scp=43449105914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43449105914&partnerID=8YFLogxK

U2 - 10.1007/s00520-007-0391-z

DO - 10.1007/s00520-007-0391-z

M3 - Article

C2 - 18197430

AN - SCOPUS:43449105914

VL - 16

SP - 421

EP - 424

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 4

ER -